AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8381187 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) - 400 mg/m2 cyclophosphamide, 40 mg/m2 doxorubicin, 60 mg/m2 cisplatin, administered in four courses at 3-week intervals starting 30 days post-surgery.
Number of subjects: 269
Study 8381187 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy).
Number of subjects: 269
Study 3116821 — intervention group
Group type: EXPERIMENTAL
Intervention: NORPLANT implants
Number of subjects: 0
Study 3116821 — intervention group
Group type: EXPERIMENTAL
Intervention: NORPLANT‐2 implants
Number of subjects: 0
Study 3116821 — intervention group
Group type: EXPERIMENTAL
Intervention: NORPLANT and NORPLANT‐2 implants
Number of subjects: 0
Study 3116821 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin treatment
Number of subjects: 0
Study 30925235 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief lifestyle self-management intervention
Number of subjects: 60
Study 30925235 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 27792961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-coping therapy (CCT)
Number of subjects: 31
Study 27792961 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy plus CCT (pCCT)
Number of subjects: 31
Study 27792961 — intervention group
Group type: COMPARATOR
Intervention: OCD patients
Number of subjects: 31
Study 26431718 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) 80 ppm for 3 days
Number of subjects: 100
Study 26431718 — intervention group
Group type: COMPARATOR
Intervention: Inhaled nitrogen placebo
Number of subjects: 100
Study 26431718 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) for patients with hypoxemia
Number of subjects: 100
Study 26431718 — intervention group
Group type: COMPARATOR
Intervention: Inhaled nitrogen placebo for patients with hypoxemia
Number of subjects: 100
Study 23920009 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) during complex motor tasks
Number of subjects: 24
Study 21395934 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroque music
Number of subjects: 0
Study 21395934 — intervention group
Group type: COMPARATOR
Intervention: Control periods
Number of subjects: 0
Study 21395934 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon shift
Number of subjects: 0
Study 18577269 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion
Number of subjects: 24
Study 18577269 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 24
Study 17003642 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard pancreaticoduodenectomy (PD)
Number of subjects: 117
Study 17003642 — intervention group
Group type: COMPARATOR
Intervention: PD with extended lymphadenectomy
Number of subjects: 117
Study 17003642 — intervention group
Group type: COMPARATOR
Intervention: Pylorus-preserving PD
Number of subjects: 117
Study 14741658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic presentation of CV syllables
Number of subjects: 0
Study 14741658 — intervention group
Group type: COMPARATOR
Intervention: Binaural presentation of CV syllables
Number of subjects: 0
Study 11473953 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg three times a day for 3 months
Number of subjects: 20
Study 11473953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11473953 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20
Study 9608770 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate + domperidone
Number of subjects: 40
Study 9608770 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine + domperidone
Number of subjects: 40
Study 9608770 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole
Number of subjects: 40
Study 9608770 — intervention group
Group type: EXPERIMENTAL
Intervention: treatment
Number of subjects: 40
Study 9608770 — intervention group
Group type: EXPERIMENTAL
Intervention: optimal treatment
Number of subjects: 40
Study 9608770 — intervention group
Group type: EXPERIMENTAL
Intervention: proton pump inhibitors
Number of subjects: 40
Study 7920492 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatients
Number of subjects: 243
Study 7920492 — intervention group
Group type: EXPERIMENTAL
Intervention: KPS <= 80
Number of subjects: 243
Study 3191018 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (eutectic mixture of lignocaine and prilocaine)
Number of subjects: 20
Study 3191018 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 20
Study 3191018 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 20
Study 31970125 — intervention group
Group type: EXPERIMENTAL
Intervention: Staples (group A)
Number of subjects: 300
Study 31970125 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular technique using monocryl 3-0 (group B)
Number of subjects: 300
Study 31970125 — intervention group
Group type: COMPARATOR
Intervention: Mattress suture nylon (2-0) (group C)
Number of subjects: 300
Study 30839400 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired nociceptive blink reflex (nBR) with inter-stimulus intervals (ISI) of 125 to 10000 milliseconds
Number of subjects: 12
Study 30839400 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned nBR/unconditioned nBR response ratio
Number of subjects: 12
Study 30839400 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude of conditioned nBR
Number of subjects: 12
Study 30839400 — intervention group
Group type: EXPERIMENTAL
Intervention: Average latency of unconditioned nR2
Number of subjects: 12
Study 28427541 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI (glycopyrrolate/formoterol 18/9.6 μg)
Number of subjects: 892
Study 25935831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet ranitidine, 150 mg; and tablet metoclopramide, 10 mg administered the night before and 2 hours before surgery
Number of subjects: 60
Study 25935831 — intervention group
Group type: COMPARATOR
Intervention: No aspiration prophylaxis
Number of subjects: 60
Study 24660591 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemic anti-deafness capsules
Number of subjects: 296
Study 24660591 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide and conventional drug treatment for deafness
Number of subjects: 296
Study 21711508 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-rich oil
Number of subjects: 19
Study 21711508 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 19
Study 21711508 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter
Number of subjects: 19
Study 19882398 — intervention group
Group type: EXPERIMENTAL
Intervention: EB‐CME approved sessions
Number of subjects: 0
Study 19882398 — intervention group
Group type: COMPARATOR
Intervention: Non EB‐CME approved sessions
Number of subjects: 0
Study 17023848 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg IV dexamethasone
Number of subjects: 61
Study 17023848 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg IV dexamethasone
Number of subjects: 61
Study 17023848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 14511896 — intervention group
Group type: EXPERIMENTAL
Intervention: β-Blockers
Number of subjects: 0
Study 14511896 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system blockers in combination with diuretics, β-blockers, or calcium channel blockers
Number of subjects: 0
Study 11115810 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 800 mg/day for 12 weeks
Number of subjects: 69
Study 11115810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 9314453 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal septic shock treatment (specific intervention details not provided)
Number of subjects: 75
Study 8392077 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg)
Number of subjects: 284
Study 8392077 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (7 mg/kg) plus dexamethasone (12 mg)
Number of subjects: 284
Study 3326676 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 100 mg
Number of subjects: 218
Study 3326676 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 200 mg
Number of subjects: 218
Study 3326676 — intervention group
Group type: COMPARATOR
Intervention: Codeine 60 mg
Number of subjects: 218
Study 3326676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 29724177 — intervention group
Group type: EXPERIMENTAL
Intervention: PREPARED
Number of subjects: 92
Study 29724177 — intervention group
Group type: EXPERIMENTAL
Intervention: PREPARED plus financial assistance
Number of subjects: 92
Study 29724177 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 92
Study 26677862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol supplementation for 6 months
Number of subjects: 276
Study 26677862 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 276
Study 26677862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol supplementation
Number of subjects: 276
Study 26677862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 25681579 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hour computerized intervention for distress intolerance (DI) over two weeks
Number of subjects: 53
Study 25681579 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no intervention)
Number of subjects: 53
Study 23973155 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (low and high dosages)
Number of subjects: 90
Study 23973155 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (low and high dosages)
Number of subjects: 90
Study 23973155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (low and high dosages)
Number of subjects: 90
Study 23973155 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dosages of NSAIDs (Celecoxib, Diclofenac, Ibuprofen)
Number of subjects: 90
Study 23973155 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID treatment
Number of subjects: 90
Study 20299286 — intervention group
Group type: EXPERIMENTAL
Intervention: Education, counseling and behavioral skill‐building program
Number of subjects: 106
Study 18304961 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim analysis of efficacy using time-related primary end points, >40% of which were overall survival.
Number of subjects: 3300
Study 18304961 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stopping of trials after interim analysis.
Number of subjects: 3300
Study 15985582 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) at a target dose of 300 mg/day
Number of subjects: 47
Study 15985582 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) at a target dose of 300 mg/day
Number of subjects: 47
Study 15985582 — intervention group
Group type: COMPARATOR
Intervention: Non-drug average
Number of subjects: 47
Study 15985582 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 47
Study 14664266 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabident intraosseous injection
Number of subjects: 41
Study 14664266 — intervention group
Group type: EXPERIMENTAL
Intervention: X-tip intraosseous injection
Number of subjects: 41
Study 11712445 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with atopic family history
Number of subjects: 52
Study 11712445 — intervention group
Group type: COMPARATOR
Intervention: Children without atopic family history
Number of subjects: 52
Study 11712445 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 8857478 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser-assisted balloon angioplasty
Number of subjects: 103
Study 8857478 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 103
Study 1512105 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (300 mg orally, b.i.d.)
Number of subjects: 401
Study 1512105 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin (500 mg orally, b.i.d.)
Number of subjects: 401
Study 6361791 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen 200 mg q.i.d.
Number of subjects: 0
Study 6361791 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 650 mg q.i.d.
Number of subjects: 0
Study 31206155 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 280
Study 31206155 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 280
Study 29425923 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopists trained in optical diagnosis with feedback
Number of subjects: 39
Study 29425923 — intervention group
Group type: COMPARATOR
Intervention: Endoscopists trained in optical diagnosis without feedback
Number of subjects: 39
Study 27543801 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes (PreDM)/Hypertension (HTN)
Number of subjects: 12808
Study 27543801 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes (PreDM)/Normal blood pressure
Number of subjects: 12808
Study 27543801 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal glucose tolerance/Prehypertension
Number of subjects: 12808
Study 27543801 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes (PreDM)/HTN
Number of subjects: 12808
Study 25398129 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary pre-dialysis education (MPE)
Number of subjects: 425
Study 25398129 — intervention group
Group type: COMPARATOR
Intervention: Non-MPE (control group)
Number of subjects: 425
Study 21430358 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Memory (WM) training consisting of five tasks trained in 10 sessions.
Number of subjects: 2
Study 21430358 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 2
Study 20589317 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg once daily
Number of subjects: 903
Study 20589317 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg once daily
Number of subjects: 903
Study 20589317 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once daily
Number of subjects: 903
Study 20589317 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 90 mg once daily
Number of subjects: 903
Study 20589317 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin (control) 2,500 IU initial, 5,000 IU subsequent doses once daily
Number of subjects: 903
Study 17521052 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive measures including fluid volume loading, discontinuation of nephrotoxic medications 48 hours prior to the study, minimizing CM volume and frequency, avoiding high-osmolar contrast in renal impairment, considering iso-osmolar contrast.
Number of subjects: 0
Study 17521052 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso-osmolar contrast
Number of subjects: 0
Study 17521052 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine (AC)
Number of subjects: 0
Study 15792898 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam
Number of subjects: 9
Study 15792898 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 11905405 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oxygen tension group (n = 17)
Number of subjects: 34
Study 11905405 — intervention group
Group type: COMPARATOR
Intervention: Low-oxygen tension group (n = 17)
Number of subjects: 34
Study 11905405 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 11057351 — intervention group
Group type: EXPERIMENTAL
Intervention: Emedastine ophthalmic solution 0.05% BID
Number of subjects: 0
Study 11057351 — intervention group
Group type: COMPARATOR
Intervention: Levocabastine ophthalmic suspension 0.05% BID
Number of subjects: 0
Study 9376749 — intervention group
Group type: EXPERIMENTAL
Intervention: Gidazepam (20 mg test dose, 40 mg daily, 14-day course)
Number of subjects: 66
Study 9376749 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazepam (0.5 mg and 1 mg test doses, daily dose 2 mg, 14-day course)
Number of subjects: 66
Study 9376749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 8251874 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended cognitive behavioral treatment (CB)
Number of subjects: 229
Study 8251874 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship enhancement (RE)
Number of subjects: 229
Study 8251874 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship and vocational enhancement (VE)
Number of subjects: 229
Study 3899091 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 2 g single oral dose
Number of subjects: 0
Study 3899091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29103126 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar total disc replacement (TDR)
Number of subjects: 82
Study 29103126 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary rehabilitation (control group)
Number of subjects: 82
Study 27687648 — intervention group
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao (YNBY)
Number of subjects: 221
Study 27687648 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 221
Study 27687648 — intervention group
Group type: EXPERIMENTAL
Intervention: YNBY in E1 subgroup
Number of subjects: 221
Study 27687648 — intervention group
Group type: COMPARATOR
Intervention: Control in E1 subgroup
Number of subjects: 221
Study 27687648 — intervention group
Group type: EXPERIMENTAL
Intervention: YNBY in E2 subgroup
Number of subjects: 221
Study 27687648 — intervention group
Group type: COMPARATOR
Intervention: Control in E2 subgroup
Number of subjects: 221
Study 27687648 — intervention group
Group type: EXPERIMENTAL
Intervention: YNBY in E3 subgroup
Number of subjects: 221
Study 27687648 — intervention group
Group type: COMPARATOR
Intervention: Control in E3 subgroup
Number of subjects: 221
Study 27687648 — intervention group
Group type: EXPERIMENTAL
Intervention: YNBY in mild cases
Number of subjects: 221
Study 27687648 — intervention group
Group type: COMPARATOR
Intervention: Control in mild cases
Number of subjects: 221
Study 27687648 — intervention group
Group type: EXPERIMENTAL
Intervention: YNBY in moderate cases
Number of subjects: 221
Study 27687648 — intervention group
Group type: COMPARATOR
Intervention: Control in moderate cases
Number of subjects: 221
Study 27687648 — intervention group
Group type: EXPERIMENTAL
Intervention: YNBY in severe cases
Number of subjects: 221
Study 27687648 — intervention group
Group type: COMPARATOR
Intervention: Control in severe cases
Number of subjects: 221
Study 27687648 — intervention group
Group type: EXPERIMENTAL
Intervention: YNBY with mesalazine
Number of subjects: 221
Study 27687648 — intervention group
Group type: COMPARATOR
Intervention: Control with mesalazine
Number of subjects: 221
Study 27687648 — intervention group
Group type: EXPERIMENTAL
Intervention: YNBY with corticosteroid
Number of subjects: 221
Study 27687648 — intervention group
Group type: COMPARATOR
Intervention: Control with corticosteroid
Number of subjects: 221
Study 27687648 — intervention group
Group type: EXPERIMENTAL
Intervention: YNBY with infliximab
Number of subjects: 221
Study 27687648 — intervention group
Group type: COMPARATOR
Intervention: Control with infliximab
Number of subjects: 221
Study 25479207 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation
Number of subjects: 70
Study 25479207 — intervention group
Group type: COMPARATOR
Intervention: Microdebrider
Number of subjects: 70
Study 23538338 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine plus daunorubicin and etoposide
Number of subjects: 523
Study 23538338 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine plus daunorubicin and etoposide
Number of subjects: 523
Study 23538338 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1203633 AA genotype
Number of subjects: 523
Study 20659966 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction and intramedullary splinting
Number of subjects: 40
Study 20659966 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment without reduction
Number of subjects: 40
Study 17590313 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) activity, 2-3 times weekly for 12 weeks using GestureTek's Gesture Xtreme video capture VR system
Number of subjects: 33
Study 16836708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (20 mg)
Number of subjects: 29
Study 16836708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (40 mg)
Number of subjects: 29
Study 16836708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 12791613 — intervention group
Group type: EXPERIMENTAL
Intervention: High-almond diet (20% of energy from almonds)
Number of subjects: 25
Study 12791613 — intervention group
Group type: COMPARATOR
Intervention: Step I diet
Number of subjects: 25
Study 10912656 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 46
Study 10912656 — intervention group
Group type: COMPARATOR
Intervention: Control (no PPIs)
Number of subjects: 46
Study 8700955 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulus condition
Number of subjects: 0
Study 8700955 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimulus condition
Number of subjects: 0
Study 1588392 — intervention group
Group type: EXPERIMENTAL
Intervention: Varying speed of arm movements with different movement times, including static trials where the arm was held still.
Number of subjects: 0
Study 1588392 — intervention group
Group type: COMPARATOR
Intervention: Static trials where the subject held the arm still at various postures (initial, final, halfway).
Number of subjects: 0
Study 31593637 — intervention group
Group type: COMPARATOR
Intervention: Placebo of vitamin D3 (n = 23)
Number of subjects: 92
Study 31593637 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplement at a dose of 50,000 IU/week (n = 23)
Number of subjects: 92
Study 31593637 — intervention group
Group type: EXPERIMENTAL
Intervention: CrPic supplement at a dose of 500 μg/day (n = 23)
Number of subjects: 92
Study 31593637 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vitamin D3 at a dose of 50,000 IU/week and CrPic at a dose of 500 μg/day (n = 23)
Number of subjects: 92